



AGENDA

Office of Pharmacy Services
 Preferred Drug List (PDL) – Pharmacy and Therapeutics Program
 Public Meeting

Thursday, November 3, 2022, 9:00am

Public Registration for ZOOM Webinar:

https://magellanhealth.zoom.us/webinar/register/WN_o9jzOuMjSMOll3eu-va_Sg

Welcome

Approval of Minutes

Timothy Romanoski, MD (Chair)

Update on the PDL Program

Mangesh Y. Joglekar, MS, PharmBS, RPH
 Chief, Clinical Services Division
 Office of Pharmacy Services

Public Presentations (up to 5 minutes each)

Preselected Speakers

PDL Prior Authorization Update

Tiffanee Lyons, PharmD
 Clinical Manager
 Conduent State Healthcare, LLC

New Business

Kara Delaney, PharmD
 Interim Pharmacist Account Manager
 Provider Synergies, LLC

Therapeutic Class Reviews	
Alzheimer’s Agents	Glucocorticoids, Inhaled
Anticonvulsants	Immunomodulators, Atopic Dermatitis
Antidepressants, Other	Intranasal Rhinitis Agents
Antidepressants, SSRIs	Leukotriene Modifiers
Antihistamines, Minimally Sedating	Neuropathic Pain
Antihypertensives, Sympatholytics	NSAIDs
Antihyperuricemics	Ophthalmics, Allergic Conjunctivitis
Antiparkinson’s Agents	Ophthalmics, Antibiotics
Antipsychotics	Ophthalmics, Antibiotic/Steroid Combinations
Bile Salts	Ophthalmics, Anti-Inflammatories
Bronchodilators, Beta Agonist	Ophthalmics, Anti-Inflammatory/Immunomodulator
Colony Stimulating Factors	Ophthalmics, Glaucoma Agents
COPD Agents	Otic Antibiotics
Cytokine and CAM Antagonists	Sedative Hypnotics
Epinephrine, Self-Injected	Stimulants and Related Agents
Erythropoiesis Stimulating Proteins	

Single Drug Reviews
Ibsrela (<i>GI Motility, Chronic</i>)
Lyvispah (<i>Skeletal Muscle Relaxants</i>)
Mounjaro (<i>Calcium Channel Blockers</i>)
Norliqva (<i>Hypoglycemics, Incretin Mimetics and Enhancers</i>)
Tyvaso DPI (<i>PAH Agents, Oral and Inhaled</i>)

*** This list may be updated closer to the November meeting date.**

Schedule Next Meeting and Adjourn

Timothy Romanoski, MD (Chair)